(CercleFinance.com) – Moderna and Merck today announced that a Phase 2b trial of an investigational personalized mRNA-based cancer vaccine candidate, in combination with Merck’s Keytruda, has demonstrated ‘statistical and clinically significant primary endpoint of recurrence-free survival (RFS) compared to Keytruda in patients with stage III/IV melanoma.
Combined with Keytruda, the treatment reduced the risk of recurrence or death by 44% compared to Keytruda alone.
‘Today’s results are very encouraging for the field of cancer treatment. mRNA has been transformative for COVID-19, and now, for the very first time, we have demonstrated the potential of mRNA to impact outcomes in a randomized clinical trial in melanoma,’ said Stéphane Bancel. , CEO of Moderna.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
